SPRO - Spero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue3,9661,979335-
Cost of Revenue33,88532,86926,33311,125
Gross Profit-29,919-30,890-25,998-11,125
Operating Expenses
Research Development----
Selling General and Administrative12,88710,8407,2232,202
Non Recurring----
Total Operating Expenses46,77243,70933,55613,327
Operating Income or Loss-42,806-41,730-33,221-13,327
Income from Continuing Operations
Total Other Income/Expenses Net1,1441,844580174
Earnings Before Interest and Taxes-42,806-41,730-33,221-13,327
Interest Expense----
Income Before Tax-41,662-39,886-32,641-13,153
Income Tax Expense----
Minority Interest355355-3,808-453
Net Income From Continuing Ops-41,662-39,886-32,641-13,153
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-41,662-38,743-25,491-10,154
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-41,662-46,097-29,928-13,427